Zymeworks Inc (ZYME) Stock AnalysisZYMEZymeworks Inc

Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zymeworks Inc is a good buy right now due to its current price of $25.79, which is significantly lower than the average analyst price target of $39, suggesting an upside potential of approximately 51%. Additionally, the company's recent acquisition of Theravance Biopharma is expected to enhance its revenue streams, with projected 2026 revenue guidance between $278 million and $292 million. However, the main risk is the company's high debt-to-equity ratio of 314.34%, which indicates potential financial instability if not managed properly.

4 analysts cover ZYME: 3 rate it Buy, 0 Hold and 1 Sell. The average price target is 35.55.